JPRN-UMIN000023515尚未招募2 期
A combination therapy of Ramucirumab and Paclitazel as second-line treatment for elderly gastric cancer patients: A exploratory phase II research - A combination therapy of Ramucirumab and Paclitazel for elderly gastric cancer patients
Dept. of Surg., Gastroenterological Center, Medical Center, Yokohama City University0 个研究点目标入组 35 人开始时间: 2016年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 75years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Unconrollable DM 2. VTE 3. MoI 4. Cerebrovascular disease 5. No GI tract bleeding or perforation 6. Uncontrollable hypertension 7. Inappropriate patient for study
研究者
相似试验
已完成
2 期
Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501)gastric cancerJPRN-jRCTs021180016Ishioka Chikashi30
未知
不适用
Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501)gastric cancerJPRN-UMIN000021728Tohoku Clinical Oncology Research and Education Society (T-CORE)30
招募中
2 期
A trial of ramucirumab plus paclitaxel combined therapy for elderly gastric cancer patientsrefractory to first-line treatmentAdvanced gastric cancer, Second-line treatment, Elderly gastric cancerJPRN-jRCT1031200158Kunisaki Chikara35
进行中（未招募）
2 期
Phase II study of ramucirumab in combination with erlotinib for untreated EGFR mutation-positive non-squamous non-small cell lung cancer patients with pleural effusion: RELAY-EffusioEGFR mutation positive advanced non-small cell lung cancerJPRN-jRCTs051210138Kaneda Hiroyasu40
招募中
2 期
Phase II study of nab-paclitaxel plus ramucirumab in combination with nivolumab in unresectable advanced or recurrent gastric cancer after progression to first-line therapy including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody.nresectable advanced or recurrent gastric cancerJPRN-jRCT2031220448Shoji Hirokazu45